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Guillain-Barre syndrome (GBS) is the most common cause of acute 
neuromuscular paralysis in children, its pathogenesis most probably involving 
an autoimmune response to Schwann cell or peripheral nerve myelin antigens. 
Steroid regimes improve demyelinating diseases such as chronic GBS. We 
assessed the benefit of high dose methylprednisolone (MP) combined with 
Intravenous immunoglobulin (MP-IVIG) and compared the effects with those of 
IVIG per se in children with GBS. 
Materials& Methods 
Thirty-six children, aged between 1-12 years were randomized to receive IV MP 
20mg/kg/day combined with IVIG 400 mg/kg/day (MP-IVIG) or IVIG per se at 
same dose for 5 days. All patients were diagnosed by standard clinical criteria 
and entered the trial within less than 2 weeks of the onset of neurological 
symptoms. All patients were too weak to walk. Functional grade (FG) was at 3 
or more (able to walk with support).
Results
In the MP-IVIG group, FG improved at least one grade after 5 days of treatment 
(P<0.05), while those who received only IVIG had no significant improvement 
in their FGs after 5 days of treatment (P<0.2). The main outcome result remained 
significantly in favor of the MP-IVIG treatment group. 
There was no significant difference in improvement of one or more FG between 
the groups, after 4 weeks of treatment (secondary outcome). 
The median time required to improve one FG was 12 days in MP-IVIG as 
compared with 21 days in IVIG per se (P<0.5), and the median time required 
to reach the stage of walking independently (FG=2) was 36 days in MP-IVIG as 
compared to 43 days in IVIG per se (P<0.03). 
Conclusion 
This study suggests that combined treatment with MP-IVIG in children with 
GBS does cause rapid improvement in the acute phase, but does not result in 
any significant difference in the long term outcome.
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Introduction 
GBS is a demyelinating disease of peripheral nerves which causes flaccid paralysis, 
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autonomic dysfunction, and minor sensory symptoms 
(1, 2). Despite modern intensive care and respiratory 
support, the mortality rate is approximately 5% and the 
rate for permanent weakness is 20% (3, 4, 5, 6).
Encouraged by the results of treatment with high 
dose methylprednisolone in adult patients with acute 
inflammatory demyelinating polyneuropathy (7,8), we 
undertook a study of this treatment in children with 
GBS. We aimed at evaluating the effect of treatment 
with the MP-IVIG combination  in children with GBS 
and to compare its effect with that of IVIG  used alone. 
The aims of this study were to determine whether there 
is an improved outcome with MP-IVIG and whether 
this treatment is safe in GBS patients. 
Materials & Methods
Thirty-six children, aged between 1 to 12 years were 
selected during 18 months, based on recommended 
clinical criteria, which were progressive motor weakness 
affecting more than one limb with or without cranial 
nerve involvement, areflexia, and absence of pleocytosis 
within 2 weeks of the onset of weakness. They were 
admitted to the Mofid Pediatric Hospital;
laboratory studies included routine testing of blood, 
urine, and cerebrospinal fluid, serum IgA measurements. 
No patients had IgA deficiency. Electromyography was 
performed after the second week of disease. 
The degree of motor function was expressed on a 7-
point functional grade (FG) scale as follows: 0, healthy; 
1, minor symptoms and signs, fully capable of manual 
work; 2, able to walk more than 5 meters without any 
assistance; 3, able to walk more than 5 meters with 
support; 4, bed or chair bound (unable to walk even 
with support); 5, assisted ventilation required for at least 
part of the day; 6, dead.
All patients who were tetraplegic, with involvement of 
autonomic system and the cranial nerves (IX, X), were 
admitted to the ICU.
Regardless of their age and sex, all patients were 
randomly divided into 2 groups, according to the 
number of patients referred to the emergency section 
(even & odd); the odd group was treated for 5 days with 
IVIG in a dose of 400 mg/kg of body weight/day and 20 
mg/kg/day of methylprednisolone intravenously (MP-
IVIG ) for 5 days. The even group received 400 mg/kg/
day IVIG per se for 5 days. 
The main outcome criterion was improvement by at 
least one functional grade after 5 days of treatment 
(Wilcoxon signed ranks test). One of the secondary 
outcome measures was the time required to improve by 
at least one functional grade after 4 weeks of treatment 
(Wilcoxon signed ranks test). The median time required 
to improve one functional grade and the median time 
required to the stage of walking independently (FG=2) 
in both groups were compared using the Wilcoxon 
two sample test (Mann Whitney test). This study 
was approved by the medical ethics committee of the 
institution consent. Written informed consent was 
obtained from all parents.
Results
Baseline characteristics are shown in table 1, and no 
significant difference was seen between the groups. In 
the MP-IVIG group, 8 of 18 patients (47%) improved 
by one FG after 5 days (P<0.05), while in the IVIG 
per se group, just 4 of 18 patients were seen to have 
made the same recovery (P<0.2). The main outcome 
result remained significantly different in favor of the 
MP-IVIG treatment group. 
In the MP-IVIG group, 13 of 17 patients improved by 
one or more FG after 4 weeks (P=0.001), as compared 
with 13 of 18 patients with IVIG per se (P=0.001). There 
was no significant difference between the groups.
The median time required to improve one FG was 12 
days in the MP-IVIG group, as compared with 21 days 
in the IVIG per se group (P<0.5), and the medium time 
required to reach the stage of walking independently 
(FG=2) was 36 days in the MP-IVIG group as compared 
to 43 days in the IVIG per se group (P<0.03).
Table 2 shows the mortality rate and residual disability 
after 6 months of follow up.
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Discussion
The study showed significant improvement of 
one FG in patients whose received high dose IV 
Methylprednisolone combined with IVIG after 5 days 
of treatment. 
In this study, we evaluated whether treatment with high 
dose IVMP and IVIG is more effective than IVIG per se 
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Table1: Patient characteristics, according to treatment group
Baseline characteristics MP-IVIG IVIG 
Number of patients 18 18
Age (mean , yr) 5.6±2.8 4.9±2.8
Duration of disease ≤ 7 days at entry (%) 72 72
FG at entry (%)
3 (ambulant with support) 3 3
4 (bedridden) 13 14
5 (artificial respiration) 2 1
History of viral infection (%) 72 77.7
CSF Protein ≥ 40 mg (%) 77.7 83
Cranial nerve involvement 22.2 27.7
Requires assisted ventilation 
(% of patients )
11.1 5.5
Length of requires ICU (mean , day) 4 4
MP = methylprednisolone; IVIG = Intravenous immunoglobulin.
Table 2: Comparison of both groups after 6 months
MP-IVIG IVIG 
Number of patients 18 18
Motor disability * 2 4
Mortality rate 1 -
* Foot drop
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in children with GBS and whether the former treatment 
is safe in patients. 
The analysis of results revealed not only that the 
MP-IVIG treatment was safe but also that it was 
significantly more effective than IVIG per se. In our 
trial, more patients in the MP-IVIG treatment group 
reached the main outcome measure of an improvement, 
by one grade on the FG scale, at 5 days. There was no 
difference between the two groups at 4 weeks. In the 
Dutch Guillain-Barre study group, 19 of 25 patients 
(76%) who received MP-IVIG improved by one or more 
FG after 4 weeks, as compared with 39 of 74 patients 
(53%) treated with IVIG per se (P=0.04). They did not 
compare FG after 5 days (7). 
Intravenous MP per se was compared with a placebo in 
the London trial, and there was no significant difference 
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in any outcome variable between patients treated with 
IVMP and those given the placebo (8). 
In our study, the median time to recover to independent 
locomotion was 36 days for the MP-IVIG treatment group 
and 43 days for the IVIG treatment group (P< 0.03).
In the Dutch GBS study group, the median time to 
recover to independent locomotion was 27 days for the 
MP-IVIG treatment group and  55 days for the IVIG 
treatment group (P=0.1) (7).
In the London trial, median time to walk unaided was 38 
days in IVMP per se patients and 50 days in the placebo 
patients (8). 
In the Dutch GBS study group, the median time until 
improvement by one FG was 20 days for the MP-IVIG 
treatment group and 27 days for the IVIG treatment 
group (P= 0.04) (7). However, in our study, the median 
time required to improve one FG was 12 days in the 
MP-IVIG treatment group and 21 days in the IVIG per 
se group (P <0.5). 
In this study, 3 patients had transient hypertension due 
to high dose MP, and one patient less than 2 years old 
developed moon face. 
In the MP-IVIG treatment group, one patient with 
persistent hypotension died in an early phase of disease 
on the second day after started medications were 
started.
Six months after medications were started for GBS, 
foot drop was seen in 2 patients (11%) in the MP-IVIG 
treatment group and in 4 patients (22%) in the IVIG per 
se treatment group. If the dead patient is included, the 
difference between the two groups was non-significant. 
The main conclusion of the study was that high dose 
MP combined with IVIG speeds recovery but does not 
lead to a better outcome, though, and is recommended 
in children severely affected with GBS. It seems that 
combination therapy may have a synergistic effect used 
in the acute phase of GBS in decreasing the immunologic 
process. 
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